Please assess the completion status of the following clinical trial:

Trial Title: LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who had received at least one dose of the study vaccine in the primary study~* Written informed consent obtained from each subject before each blood sampling visit~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 20 Years
- Healthy Volunteers: t

Study Arms:
- Engerix 4D + HBIg Group (Type: EXPERIMENTAL): Subjects received Engerix™ (hepatitis B vaccine \[HBV\]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
- Engerix 3D + HBIg Group (Type: EXPERIMENTAL): Subjects received Engerix™ (hepatitis B vaccine \[HBV\]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
- Engerix 4D (Type: EXPERIMENTAL): Subjects received Engerix™ (hepatitis B vaccine \[HBV\]) at Month 0, 1, 6 and 60.
- Engerix 3D Group (Type: EXPERIMENTAL): Subjects received Engerix™ (hepatitis B vaccine \[HBV\]) at Month 0, 1, and 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).